Effects of add-on montelukast on airway hyperresponsiveness in patients with well-controlled asthma - a pilot study

Nina Kononowa, Sandra Michel, David Miedinger, Christiane E Pichler, Prashant N Chhajed, Arthur Helbling, Jörg D Leuppi, Nina Kononowa, Sandra Michel, David Miedinger, Christiane E Pichler, Prashant N Chhajed, Arthur Helbling, Jörg D Leuppi

Abstract

Objective: Control of airway inflammation is the cornerstone of asthma management. The aim of the present pilot study was to assess the effects of a leukotriene receptor antagonist (LTRA) added to a basic treatment of inhaled corticosteroids (ICS) and long-acting beta-agonist (LABA) on airway hyperresponsiveness, inflammation, and quality of life in well-controlled patients with asthma.

Research design and methods: Seventeen patients (age 18-65, 11 women) with well-controlled asthma presenting airway hyperresponsiveness to mannitol and methacholine challenge were given add-on montelukast on a stable ICS + LABA for 4 weeks. Quality of life and selected parameters of airway inflammation were measured at baseline and at study end. (ClinicalTrials.gov (NCT01725360)).

Results: Adding montelukast to ICS + LABA resulted in an increase in mean FEV1 (+4.5%, p = 0.057), cumulated higher dose of mannitol (+32.5%, p = 0.023) and methacholine (+17.2%, 0.237) in the provocation test, lower airway reactivity with mannitol and methacholine (response dose ratio (RDR) -50.0%, p = 0.024 and -44.3%, p = 0.006, respectively), and improved airway sensitivity to mannitol and methacholine (+12.1%, p = 0.590 and +48.0%, p = 0.129 for PD15 and PD20 FEV1, respectively). Changes in inflammation parameters (blood eosinophil count, serum eosinophil cationic protein, and exhaled nitric oxide) were consistent with these findings. Asthma-related quality of life improved significantly in all domains and overall (from 5.3 at baseline to 6.1 at the final visit, p < 0.001). The main limitation was the absence of a control group.

Conclusion: The consistency of the changes in airway hyperresponsiveness and inflammation as well as in quality of life observed with an add-on therapy with montelukast in well-controlled asthma patients during 4 weeks suggests that residual inflammation may represent an area for further improvement of asthma control to be explored in adequately powered randomized controlled trials.

Keywords: AHR, Airway hyperresponsiveness; AQLQ, Asthma Quality of Life Questionnaire; BHR, Bronchial hyperreactivity; BPT, Bronchial provocation test; ECP, Eosinophil cationic protein; FeNO, Fraction of exhaled nitric oxide; FEV1, Forced expiratory volume in one s; Airway hyperresponsiveness; Airway inflammation; Asthma; Asthma control; Leukotriene receptor antagonists; Mannitol provocation test; Methacholine provocation test.

References

    1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Available from: . Last accessed December 15, 2011
    1. Pavord ID Ward R Woltmann G et al. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999;60:1905-9
    1. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol 2007;120:1269-75
    1. Bjermer L. Evaluating combination therapies for asthma: pros, cons, and comparative benefits. Ther Adv Respir Dis 2008;2:149-61
    1. Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol 2006;97:731-41, quiz 741-32, 793
    1. Kraft M Cairns CB Ellison MC et al. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006;130:1726-32
    1. Barnes NC. Effects of antileukotrienes in the treatment of asthma. Am J Respir Crit Care Med 2000;161:S73-6
    1. Diamant Z Grootendorst DC Veselic-Charvat M et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999;29:42-51
    1. Vaquerizo MJ Casan P Castillo J et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-10
    1. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001;357:2007-11
    1. Phipatanakul W Greene C Downes SJ et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003;91:49-54
    1. Dupont L Potvin E Korn D et al. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005;21:863-9
    1. Bjermer L Bisgaard H Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327:891.
    1. Ilowite J Webb R Friedman B et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004;92:641-8
    1. Stelmach I Grzelewski T Bobrowska-Korzeniowska M et al. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulm Pharmacol Ther 2007;20:691-700
    1. Fritscher LG Rodrigues MT Zamel N et al. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med 2009;103:296-300
    1. Anderson SD. Indirect challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010;138:25-30S
    1. Standardization of Spirometry, 1994 Update American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36
    1. Quanjer PH Tammeling GJ Cotes JE et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993 Mar;16:5-40
    1. Anderson SD Brannan J Spring J et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997;156:758-65
    1. Martin BW Ackermann-Liebrich U Leuenberger P et al. SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults. Soz Praventivmed 1997;42:67-84
    1. Burney PG Luczynska C Chinn S et al. The European Community Respiratory Health Survey. Eur Respir J 1994;7:954-60
    1. Chinn S Burney P Jarvis D et al. Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1997;10:2495-501
    1. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999 This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 1999;160:2104-17
    1. Juniper EF Guyatt GH Epstein RS et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83
    1. Leuppi JD Anderson SD Brannan JD et al. Questionnaire responses that predict airway response to hypertonic saline. Respiration 2005;72:52-60
    1. Scherr A Schafroth Torok S Jochmann A et al. Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol. Chest 2012;142:919-26
    1. Pauwels R, Joos G, Van der Straeten M. Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma. Clin Allergy 1988;18:317-21
    1. Joos GF O'Connor B Anderson SD et al. Indirect airway challenges. Eur Respir J 2003;21:1050-68
    1. Anderson SD Charlton B Weiler JM et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009 Jan 23;10:4.. doi: 10.1186/1465-9921-10-4
    1. Cockcroft DW. How best to measure airway responsiveness. Am J Respir Crit Care Med 2001;163:1514-15
    1. Leuppi JD Salome CM Jenkins CR et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-12
    1. Leuppi JD Salome CM Jenkins CR et al. Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma. Eur Respir J 2001;18:444-50
    1. Lee DK Haggart K Currie GP et al. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Br J Clin Pharmacol 2003;55:639-42
    1. Currie GP Haggart K Lee DK et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy 2003;33:783-8
    1. Brannan JD Anderson SD Perry CP et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 2005;6:144.. doi: 10.1186/1465-9921-6-144
    1. Boulet LP. Asymptomatic airway hyperresponsiveness: a curiosity or an opportunity to prevent asthma? Am J Respir Crit Care Med 2003;167:371-8
    1. McGrath KW, Fahy JV. Negative methacholine challenge tests in subjects who report physician-diagnosed asthma. Clin Exp Allergy 2011;41:46-51
    1. Ramsdale EH Morris MM Roberts RS et al. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol 1985;75:573-7
    1. Ramsdale EH Morris MM Roberts RS et al. Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax 1984;39:912-18
    1. Crapo RO Casaburi R Coates AL et al. Guidelines for methacholine and exercise challenge testing – 1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-29
    1. O'Connor G Sparrow D Taylor D et al. Analysis of dose-response curves to methacholine. An approach suitable for population studies. Am Rev Respir Dis 1987;136:1412-17
    1. Jayet PY Schindler C Kunzli N et al. Reference values for methacholine reactivity (SAPALDIA study). Respir Res 2005;6:131.. doi: 10.1186/1465-9921-6-131
    1. Ringdal N. Long-acting beta2-agonists or leukotriene receptor antagonists as add-on therapy to inhaled corticosteroids for the treatment of persistent asthma. Drugs 2003;63(Suppl 2):21-33
    1. Joos S Miksch A Szecsenyi J et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008;63:453-62
    1. Keith PK Koch C Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16(Suppl A):17-31A
    1. Ulrik CS, Diamant Z. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing. Clin Exp Allergy 2010;40:576-81
    1. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J 1997;10:1683-93
    1. Petsky HL Cates CJ Lasserson TJ et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208
    1. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004;25:477-82
    1. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998;50:515-96
    1. Holgate ST Peters-Golden M Panettieri RA et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003;111:S18-34; discussion S34-16
    1. Peters-Golden M. Expanding roles for leukotrienes in airway inflammation. Curr Allergy Asthma Rep 2008;8:367-73
    1. Walters EH Reid DW Johns DP et al. Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling. Eur Respir J 2007;30:574-88
    1. Ramsay CF Sullivan P Gizycki M et al. Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial. Respir Med 2009;103:995-1003
    1. Minoguchi K Kohno Y Minoguchi H et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002;121:732-8
    1. Ricciardolo FL. Multiple roles of nitric oxide in the airways. Thorax 2003;58:175-82
    1. Grob NM, Dweik RA. Exhaled nitric oxide in asthma: progress since the introduction of standardized methodology. J Breath Res 2008;2:37002.
    1. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care 2005;Med 171:912-30
    1. Kanazawa H Shoji S Yoshikawa T et al. Increased production of endogenous nitric oxide in patients with bronchial asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 1998;28:1244-50
    1. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70
    1. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996;153:454-7
    1. Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly 2002;132:151-8
    1. Peters-Golden M, Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation. J Allergy Clin Immunol 2003;111:S37-42; discussion S43-38
    1. Leander M Lampa E Janson C et al. Determinants for a low health-related quality of life in asthmatics. Ups J Med Sci 2012;117:57-66
    1. Canonica GW Bousquet J Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62 Suppl 85:17-25
    1. Taegtmeyer AB Steurer-Stey C Price DB et al. Predictors of asthma control in everyday clinical practice in Switzerland. Curr Med Res Opin (2009;25:2549-55

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel